Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
NCT00416455 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 384
Last updated 2019-07-23
Summary
This phase I/II trial is studying how well fludeoxyglucose F 18 PET scan, CT scan, and ferumoxtran-10 MRI scan finds lymph node metastasis before undergoing chemotherapy and radiation therapy in patients with locally advanced cervical cancer or high-risk endometrial cancer. Diagnostic procedures, such as a fludeoxyglucose F 18 positron emission tomography (PET) scan, computed tomography (CT) scan, and ferumoxtran-10 magnetic resonance imaging (MRI) scan, may help find lymph node metastasis in patients with cervical cancer or endometrial cancer.
Conditions
- Cervical Adenocarcinoma
- Cervical Adenosquamous Cell Carcinoma
- Cervical Small Cell Carcinoma
- Cervical Squamous Cell Carcinoma
- Endometrial Clear Cell Carcinoma
- Endometrial Papillary Serous Carcinoma
- Stage I Endometrial Carcinoma
- Stage IB Cervical Cancer
- Stage II Endometrial Carcinoma
- Stage IIA Cervical Cancer
- Stage IIB Cervical Cancer
- Stage III Cervical Cancer
- Stage III Endometrial Carcinoma
- Stage IVA Cervical Cancer
Interventions
- RADIATION
-
fludeoxyglucose F 18
Undergo FDG PET/CT
- PROCEDURE
-
positron emission tomography
Undergo FDG PET/CT
- PROCEDURE
-
computed tomography
Undergo FDG PET/CT
- DRUG
-
ferumoxtran-10
Undergo femoxtran-10 MRI
- PROCEDURE
-
magnetic resonance imaging
Undergo femoxtran-10 MRI
- PROCEDURE
-
diagnostic lymphadenectomy
Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy
- PROCEDURE
-
lymph node biopsy
Undergo pelvic and abdominal lymph node biopsy
Sponsors & Collaborators
-
NRG Oncology
collaborator OTHER -
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Mostafa Atri · NRG Oncology
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-09-30
- Primary Completion
- 2014-09-30
- Completion
- 2016-07-16
Countries
- United States
- Canada
- Japan
- South Korea
Study Locations
More Related Trials
-
Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR
NCT05047913 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
NCT00559377 ·Status: COMPLETED ·Phase: PHASE2
-
[18F]-AraG PET Imaging in LA HNSCC
NCT07168785 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer
NCT03575949 ·Status: COMPLETED ·Phase: NA
-
Detection of Cervical Lymph Node Metastases With a High-Resolution Positron Emission Tomography (PET) Imaging System
NCT01030497 ·Status: COMPLETED
-
PET/MRI Scan for the Evaluation of Resectable Stage IA1-IB3 Cervical Cancer
NCT04219904 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Positron Emission Tomography in Patients With Breast Cancer
NCT00001385 ·Status: COMPLETED
-
PET/MRI in Endometrial Cancer
NCT05390021 ·Status: WITHDRAWN ·Phase: NA
-
Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Cervical Heterogenity Imaging Study
NCT00907140 ·Status: COMPLETED ·Phase: NA
-
[18F]FES PET/.CT in Uterine Cancer
NCT05916196 ·Status: RECRUITING ·Phase: PHASE2
-
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
NCT04510311 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy
NCT01663753 ·Status: COMPLETED ·Phase: NA
-
Para-Aortic Lymph Nodal Staging & Evaluation of Treatment Outcome by 18F FDG-PET in Advanced Cancer Cervix
NCT00193752 ·Status: COMPLETED
-
FLT PET Imaging for Cervical Cancer
NCT01075412 ·Status: TERMINATED ·Phase: PHASE2
-
FDG-PET/CT in Assessing the Tumor and Planning Neck Surgery in Patients With Newly Diagnosed H&N Cancer
NCT00983697 ·Status: UNKNOWN ·Phase: NA
-
Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)
NCT06083103 ·Status: RECRUITING
-
Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer
NCT01655745 ·Status: COMPLETED ·Phase: NA
-
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
NCT00588185 ·Status: RECRUITING ·Phase: NA
-
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
NCT04316117 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
NCT00019565 ·Status: COMPLETED ·Phase: PHASE1
-
Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery
NCT02112162 ·Status: TERMINATED ·Phase: PHASE1
-
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
NCT04752267 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Prognostic Utility of the Imaging and Biological Signatures in Nasopharyngeal Carcinoma
NCT04417985 ·Status: COMPLETED ·Phase: NA
-
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
NCT06145399 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer
NCT00671437 ·Status: COMPLETED ·Phase: PHASE2